Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 230-256-0 | CAS number: 6990-06-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
A screening for reproductive/developmental toxicity of fusidic acid in male Sprague Dawley rats was performed in accordance to ICH testing guideline and following GLP.
Sodium fusidate administered by oral gavage to male Sprague Dawley rats for 28 days at dose level of 0, 100, 200 and 400 mg/kg bw. prior to mating with untreated females did not affect the mating performance or the spermatogenic cycle. Pregnancy outcome were similar in the four groups. No effects were observed on number of corpora lutea, implantations, early and late resorptions and litter size when compared to the vehicle control.
Based on these data, a NOAEL of 400 mg/kg bw/d could be established.
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 13 January 1997- 16 March 1997
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- other: ICH test guidelines
- Version / remarks:
- Note for Guidance on reproductive Toxicology. Detection of toxicity to reproduction for medical products (CPMP/ICH//386/95, ICH TopicS5A)
and Note for Guidance on reproductive Toxicology. Toxicity on male fertility (CPMP/ICH/136/95, ICH Topic S5B)
Comparable to OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test) - Deviations:
- not specified
- Principles of method if other than guideline:
- The effect of sodium fusidate on the male fertility in rats was studied.
4 groups each containing 25 males and 25 females were examined.
Males were exposed to either 0 (vehicle), 100 ; 200 mg; or 400 mg/kg bw/day. Females were not exposed.
Males were exposed to sodium fusidate by oral gavage for four weeks.
Females were placed overnight (4p.m. to 8 a.m.) with the males and then returned to their home cage.
Mating procedure was repeated until mating occured or for at least 14 days.
Mortality, growth and fertility was studied following the oral exposure. - GLP compliance:
- yes
- Limit test:
- no
- Specific details on test material used for the study:
- Sodium fusidate
Batch no. C4532 - Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- (Mol: SPRD)
Age: 8 weeks
Weight: 200g (female) and 275g (male)
Møllegaard Breeding Center, Ejby, Denmark
Acclimatisation: 14 days
1 control and 3 treatment groups (25 males and 25 females)
Males: treated twice per day for 7 days/ week; Females: no treatment - Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- 100 male and 100 female rats
- Route of administration:
- oral: gavage
- Vehicle:
- other: Disodium phosphate dihydrate (19.6 mg); citric acid monohydrate (1 mg/L); Disodium edetate (0.5 mg), Water (1 mL)
- Details on exposure:
- Males: treated twice per day for 7 days/ week
Females: no treatment
Duration 4 weeks - Details on mating procedure:
- Mating ration: 1 female per male.
Females were placed overnight (4p.m. to 8 a.m.) with the males and then returned to their home cage.
Mating procedure was repeated until mating occured or for at least 14 days. - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- NA
- Duration of treatment / exposure:
- 4 weeks exposure followed by up to 2 weeks mating
- Frequency of treatment:
- twice/day
- Details on study schedule:
- NA
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- vehicle
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Remarks:
- administrated as 2*50 mg/kg bw/day
- Dose / conc.:
- 200 mg/kg bw/day (nominal)
- Remarks:
- administrated as 2*100 mg/kg bw/day
- Dose / conc.:
- 400 mg/kg bw/day (nominal)
- Remarks:
- administrated as 2*200 mg/kg bw/day
- No. of animals per sex per dose:
- 25 males
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- daily observations: health and behaviour
- Positive control:
- not included
- Parental animals: Observations and examinations:
- daily observations
- Oestrous cyclicity (parental animals):
- na
- Sperm parameters (parental animals):
- na
- Litter observations:
- Number of corpora lutea
Number of implantations
Number of viable and dead offspring
The litter size - Postmortem examinations (parental animals):
- na
- Postmortem examinations (offspring):
- na
- Statistics:
- na
- Reproductive indices:
- na
- Offspring viability indices:
- na
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Regurgitation of the test substance followed aspiration into the lungs was observed in a proportion of the treated males. Clinical signs were dyspnea with gasping and wheezing respiration sound, red serous fluid from the nose. Reduced spontaneous activity and piloerection.These observations were treatment and dose related and not observed in the vehicle control.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- One female (group 1) was killed due to a growth at the front leg. 11 males (2 group 2 males; one group 3 male and 8 group 4 males) were found dead or prematurely killed for humane reasons due to aspiration of the sodium fusidate solution, which is very irritative.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No effects on growth observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- Activity: Reduced spontaneous activity and piloerection.
Mating performance: No difference between the exposure and vehicle control groups - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related changes observed.
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not specified
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- There was no difference in the mating performance in the vehicle and the sodium fusidate treated groups (copulation, fertility, and gestation indices). The time to successful mating (mating days) and the number of corpora lutea, implantations, early and late resorption, and litter size, were comparable in the vehicle control and the three groups where the males were treated with sodium fusidate prior to mating. The calculated pre-implantation loss varied widely in the four groups, but the difference was not treatment- or dose related. The post-implantation loss was comparable in the four groups of pregnant female rats.
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- >= 400 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- organ weights and organ / body weight ratios
- reproductive performance
- Key result
- Dose descriptor:
- LOAEC
- Effect level:
- ca. 100 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- mortality
- Remarks on result:
- other: The death were attributed to regurgitation of the test substance by aspiration into the lungs. This is a known effect of sodium fusidate, which is locally very irritative. The incident of these deaths were clearly dose-related.
- Clinical signs:
- not examined
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- not examined
- Body weight and weight changes:
- not examined
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- not examined
- Clinical signs:
- not examined
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Litter size were comparable in the vehicle control and the treated groups
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Histopathological findings:
- not examined
- Other effects:
- not examined
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOEL
- Generation:
- F1
- Effect level:
- > 400 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- viability
- Key result
- Dose descriptor:
- NOEL
- Generation:
- F1
- Effect level:
- > 400 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: number of corpera lutea, implantations, early and late resorptions and litter size
- Clinical signs:
- not examined
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- not examined
- Body weight and weight changes:
- not examined
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Histopathological findings:
- not examined
- Other effects:
- not examined
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Reproductive effects observed:
- no
- Lowest effective dose / conc.:
- 400 mg/kg bw/day (actual dose received)
- Treatment related:
- no
- Conclusions:
- Sodium fusidate administered by oral gavage to male Sprague Dawley rats for 28 days at dose level of 0, 100, 200 and 400 mg/kg bw. prior to mating with untreated females did not affect the mating performance or the spermatogenic cycle. Pregnancy outcome were similar in the four groups. No effects were observed on number of corpora lutea, implantations, early and late resorptions and litter size when compared to the vehicle control.
A number of males were found dead or prematurely killed for humane reasons. The death that occurred in some of the males in the three treatment groups were attributed to regurgitation of the test substance by aspiration into the lungs. This is a known effect of sodium fusidate, which is locally very irritative. The incident of these deaths was clearly dose-related.
In conclusion, no effects were seen on the reproductive performance or fertility of the male rats at the maximum tolerable dose level. Based on these data, a NOAEL of 400 mg/kg bw/d could be established. - Executive summary:
A screening for reproductive / developmental toxicity of fusidic acid in male Sprague Dawley rats was performed in accordance to ICH testing guideline and following GLP.
Sodium fusidate administered by oral gavage to male Sprague Dawley rats for 28 days at dose level of 0, 100, 200 and 400 mg/kg bw. prior to mating with untreated females did not affect the mating performance or the spermatogenic cycle. Pregnancy outcome were similar in the four groups. No effects were observed on number of corpora lutea, implantations, early and late resorptions and litter size when compared to the vehicle control.
A number of males were found dead or prematurely killed for humane reasons. The death that occurred in some of the males in the three treatment groups were attributed to regurgitation of the test substance by aspiration into the lungs. This is a known effect of sodium fusidate, which is locally very irritative. The incident of these deaths was clearly dose-related.
In conclusion, no effects were seen on the reproductive performance or fertility of the male rats at the maximum tolerable dose level. Based on these data, a NOAEL of 400 mg/kg bw/d could be established.
Reference
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- A screening for reproductive / developmental toxicity available (Key study - Klimich score 1).
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Effects on developmental toxicity
Description of key information
A key screening study for reproductive/developmental toxicity of fusidic acid in male Sprague Dawley rats was performed in accordance to ICH testing guideline and following GLP.
Sodium fusidate administered by oral gavage to male Sprague Dawley rats for 28 days at dose level of 0, 100, 200 and 400 mg/kg bw. prior to mating with untreated females did not affect the mating performance or the spermatogenic cycle. Pregnancy outcome were similar in the four groups. No effects were observed on number of corpora lutea, implantations, early and late resorptions and litter size when compared to the vehicle control. Based on these data, a NOAEL of 400 mg/kg bw/d could be established.
Supportive data available from a prenatal non-GLP developmental toxicity study performed in pregnant rats, mice and rabbits to examine the possible teratogenic effects of fusidin acid.
Rats and mice were dosed orally with 0, 20, 100, 200 mg/kg bw/d for 12 days (rats, day 3-15 of gestation) or 9 days (mice, day 6-15 of gestation). Rabbits were dosed orally with 0, 125 mg/kg bw/d for 12 days (day 6-18 of gestation). No test-item related toxicity and adverse effects observed. Thus, based on the results of this study using three species (mice/rats/rabbits), the dose level of 200 mg fusidin acid/kg/ bw/d can be considered as the No Observed Adverse Effect Level (NOAEL) for maternel toxicity as well as for developmental effects.
Supportive data available from a non-GLP developmental toxicity study was performed in rats using dose levels of 0 and 400 mg/kg bw/d. No test-item related toxicity and adverse effects observed. Thus, based on the results of this study using FDLR-rats, the dose level of 400 mg fusidin acid/kg/ bw/d can be considered as the No Observed Adverse Effect Level (NOAEL) for maternel toxicity as well as for developmental effects.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1965
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Principles of method if other than guideline:
- Rats:
Pregnant rats were devided into 3 groups of 29-31 animals and exposed from day 3-15 of gestation.
Dosing: 0, 20, 100, 200 mg/kg bw/day (control 59 pregnant rats, reciving water by oral tube)
On day 21 half the animals were killed and examined. Remaining animals were allowed to continue until term.
Endpoints examined: average number of foetus and average weight, average length of pregnancy, average number of young, average weight of young, average no. of mothers with dead foetus, number of dead foetus, number of still-born, no. ofyoung with subcutaneous haematomas at birth, average no. of weanlings, mortality during lactation period,average weight at weaning
Mice:
Pregnant mice were devided into 3 groups of 16-19 animals and exposed from day 6-15 of gestation.
Dosing: 0, 20, 100, 200 mg/kg bw/day (control 23 pregnant mice, reciving water by oral tube)
On day 18 half the animals were killed and examined. Remaining animals were allowed to continue until term.
Endpoints examined: average number of foetus and average weight, average no. of mothers with dead foetus, number of dead foetus, average length of pregnancy, average litter size, average weight, average number of weanlings,mortality during lactation period, average weight at weaning
Rabbits:
Pregnant rabbits were exposed from day 6-18 of gestation.
Dosing: 0, 125 mg/kg bw/day (control 11 pregnant rabbits, reciving placebo tablets)
On day 30 half the animals were killed and examined .Remaining animals were allowed to continue until term.
Endpoints examined: average number of foetus and average weight, average number of young and average weight of young - GLP compliance:
- no
- Limit test:
- no
- Specific details on test material used for the study:
- Sodium fusidate
- Species:
- other:
- Strain:
- other: albino rats; albino mice, rabbits (Danish white breed)
- Route of administration:
- other: Rats and mice: oral drinking water. Rabbits: tablets
- Vehicle:
- not specified
- Details on exposure:
- Rats:
Pregnant rats were devided into 3 groups of 29-31 animals and exposed from day 3-15 of gestation.
Dosing: 0, 20, 100, 200 mg/kg bw/day (control 59 pregnant rats, reciving water by oral tube)
Mice:
Pregnant mice were devided into 3 groups of 16-19 animals and exposed from day 6-15 of gestation.
Dosing: 0, 20, 100, 200 mg/kg bw/day (control 23 pregnant mice, reciving water by oral tube)
Rabbits:
Pregnant rabbits were exposed from day 6-18 of gestation.
Dosing: 0, 125 mg/kg bw/day (control 11 pregnant rabbits, reciving placebo tablets) - Analytical verification of doses or concentrations:
- not specified
- Details on mating procedure:
- animals pregnant at initiation of the study
- Duration of treatment / exposure:
- rat: 12d (3-15 of gestation)
mice: 9d (day 6-15 of gestation.)
rabbits: 12d (day 6-18 of gestation) - Frequency of treatment:
- daily dose of either 0, 20, 100 or 200 mg/kg bw.
- Duration of test:
- rat: 21d
mice: 18d
rabbits: 30d - Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 20 mg/kg bw/day (nominal)
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 200 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- only pregnant females were exposed:
rat: 29-31
mice: 16-19
rabbits: 18 - Control animals:
- yes, concurrent no treatment
- Details on study design:
- please refer to above section: principles of method if other than guideline
- Maternal examinations:
- duration of pregnancy (mice and rat)
number of mothers with dead foetuses/ number of dead foetus (mice and rat)
number of mothers with stillborn (rat) - Fetal examinations:
- average number
average weight
subcutaneous haematomas - Statistics:
- NA
- Indices:
- NA
- Historical control data:
- NA
- Clinical signs:
- not examined
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- not examined
- Body weight and weight changes:
- not examined
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
- Number of abortions:
- not examined
- Pre- and post-implantation loss:
- not examined
- Total litter losses by resorption:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Mice: The rather large number of partially absorbed foetuses seen in all groups at autopsy, is probably due to mothers discomfort from the daily oral administration
- Early or late resorptions:
- not examined
- Dead fetuses:
- no effects observed
- Description (incidence and severity):
- rat: number of stillborn examined: No effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- Rats: Number of stillborn
Mice, rabbit: Litter size
All: average number of young, distribution male/female - Details on maternal toxic effects:
- no effects
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- rat, mice and rabbit
- Effect level:
- >= 200 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Abnormalities:
- not examined
- Fetal body weight changes:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- effects observed, treatment-related
- Description (incidence and severity):
- Rabbit: Litter size was rather low in the fusidin treatment group. Findings might be explained by the fact that intestinal disturbances (loose stool, decreased appetite) were encountered more often among mothers treated with the antibiotic and could be ascribed to an alternation in the intestinal flora.
- Changes in postnatal survival:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Rats: rather high mortality is believed to be caused by manipulative procedures with mother and young
- External malformations:
- not examined
- Skeletal malformations:
- not examined
- Visceral malformations:
- not examined
- Other effects:
- not specified
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 200 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reduction in number of live offspring
- changes in sex ratio
- fetal/pup body weight changes
- changes in litter size and weights
- changes in postnatal survival
- Remarks on result:
- other: Rats: high ratio of mortality in all groups during gestation and lactation period, not treatment related
- Abnormalities:
- not examined
- Conclusions:
- A prenatal non-GLP developmental toxicity study was performed in pregnant rats, mice and rabbits to examine the possible teratogenic effects of fusidin acid.
No test-item related toxicity and adverse effects observed using dose levels of 0, 20, 100, 200 mg/kg bw/d (rats/mice) or 0, 125 mg/kg bw/d (rabbits). Thus, based on the results of this study using three species (mice/rats/rabbits), the dose level of 200 mg fusidin acid/kg/ bw/d can be considered as the No Observed Adverse Effect Level (NOAEL) for maternel toxicity as well as for developmental effects. - Executive summary:
A prenatal non-GLP developmental toxicity study was performed in pregnant rats, mice and rabbits to examine the possible teratogenic effects of fusidin acid.
Rats and mice were dosed orally with 0, 20, 100, 200 mg/kg bw/d for 12 days (rats, day 3-15 of gestation) or 9 days (mice, day 6-15 of gestation). Rabbits were dosed orally with 0, 125 mg/kg bw/d for 12 days
(day 6-18 of gestation).
No test-item related toxicity and adverse effects observed. Thus, based on the results of this study using three species (mice/rats/rabbits), the dose level of 200 mg fusidin acid/kg/ bw/d can be considered as the No Observed Adverse Effect Level (NOAEL) for maternel toxicity as well as for developmental effects.
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1966
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Principles of method if other than guideline:
- 2 groups of 20 rats of each sex were exposed to sodium fusidate.
Average daily intake of 0 and 400 mg/kg bw. (14 days)
After 14 days one male and one female were grouped for mating.
One day 20 of gestation foetuses were taken by cacsarean section from 10 dams.
The uterus were examined. Implant sites were counted and compared to number of viable foetus, which were counted and weighed.
Foetal skeletal structures were examined under a disecting microscope. Internal organs were also examined for abnormalties.
Remaining 10 dams were permitted to cast their litter naturally. Pubs were counted and weighed.
Survivors were sacrified and organs examined at necropsy: liver, spleen, stomac, small and large intestines, pancreas, kidney, bladder, adrenals, gonads,adnexa, thyroids,pituitaries, thymus,salivary glands, lymph nodes, heart, aorta, lungs, sternum, skin,, spinal cord, brain and eyes. - GLP compliance:
- no
- Limit test:
- no
- Specific details on test material used for the study:
- Sodium fusidate
SQ 16, 360 Batch no.13 - Species:
- rat
- Strain:
- other: FDRL
- Details on test animals or test system and environmental conditions:
- FDLR-rats of proven fertility
- Route of administration:
- oral: feed
- Details on exposure:
- Please refer to section "details on exposure if other than guideline"
- Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- NA
- Details on mating procedure:
- After 14 days of exposure, one male and one female were grouped for mating.
- Duration of treatment / exposure:
- 14 days prior to mating
- Frequency of treatment:
- Daily exposure via food
- Duration of test:
- Following exposure: up to 20 days of gestation
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 400 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 20 rats of each sex per dose
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- Please refer to section "details on exposure if other than guideline"
- Maternal examinations:
- Females where foetuses were taken by cacsarean section were examined
- Ovaries and uterine content:
- Uterus examination
No of implant sites - Fetal examinations:
- Dams where foetuses were taken by cacsarean section
- Number of viable foetus, were counted and weighed.
- Foetal skeletal structures were examined under a disecting microscope. Internal organs were also examined for abnormalties.
Pubs from remaining 10 dams which were permitted to cast their litter naturally.
- Pubs were counted and weighed.
- Survivors were sacrified and organs examined at necropsy: liver, spleen, stomac, small and large intestines, pancreas, kidney, bladder, adrenals, gonads,adnexa, thyroids,pituitaries, thymus,salivary glands, lymph nodes, heart, aorta, lungs, sternum, skin,, spinal cord, brain and eyes. - Statistics:
- NA
- Indices:
- Fertility (percent of mating resulting inpregnacies)
Gestation (percent of pregnacies resulting in litters cast alive)
Viability (Percent of pubs cast alive that survived at 4 days)
Lactation (Percent of pubs alive at day 4 that survived to weaning at 21 days) - Historical control data:
- NA
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Description (incidence and severity):
- oral study
- Mortality:
- not specified
- Description (incidence):
- All females except one surved the study
- Body weight and weight changes:
- not specified
- Description (incidence and severity):
- Body weight reported. No information on weight changes
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not specified
- Description (incidence and severity):
- examination of uterus
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not specified
- Description (incidence and severity):
- Examination of uterus was conducted but not described
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- Two control females had no pregnancies, however uterus examination indicated that there had been no implanted fetuses
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- not examined
- Changes in number of pregnant:
- no effects observed
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- > 400 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- dead fetuses
- early or late resorptions
- number of abortions
- pre and post implantation loss
- total litter losses by resorption
- Fetal body weight changes:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- not examined
- Changes in litter size and weights:
- effects observed, treatment-related
- Description (incidence and severity):
- The body weight of the weanlings in the exposure group was significantly higher than the body weight of the control group
- Changes in postnatal survival:
- no effects observed
- External malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Three fetuses in the control group had massive hematomas in the neck
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Approximately 4% of the pups in each group, had bone abnormalties
- Visceral malformations:
- not specified
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 400 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reduction in number of live offspring
- fetal/pup body weight changes
- changes in litter size and weights
- changes in postnatal survival
- external malformations
- skeletal malformations
- Conclusions:
- A non-GLP developmental toxicity study was performed in rats using dose levels of 0 and 400 mg/kg bw/d. No test-item related toxicity and adverse effects observed. Thus, based on the results of this study using FDLR-rats, the dose level of 400 mg fusidin acid/kg/ bw/d can be considered as the No Observed Adverse Effect Level (NOAEL) for maternel toxicity as well as for developmental effects.
- Executive summary:
The effects of sodium fusidate on mating and in utero neonatal development was studied in FDLR-rats, which were exposed orally to 400 mg/kg bw/day for 14 days before mating.
No test-item related toxicity and adverse effects observed. Thus, based on the results of this study using FDLR-rats, the dose level of 400 mg fusidin acid/kg/ bw/d can be considered as the No Observed Adverse Effect Level (NOAEL) for maternel toxicity as well as for developmental effects.
Referenceopen allclose all
Data show that 634 foetuses and young from 89 treated rats do not deviate from 447 foetuses and young from 59 control rats.
Data show that 352 foetuses and young from 52 treated mice do not deviate from 179 foetuses and young from 23 control mice.
Data show that 91 foetuses and young from 18 treated rabbits do not deviate from 86 foetuses and young from 11 control rabbits.
control test
Fertility (percent of mating resulting inpregnacies) 100 100
Gestation (percent of pregnacies resulting in litters cast alive) 100 70*
Viability (Percent of pubs cast alive that survived at 4 days) 55.6 89.3
Lactation (Percent of pubs alive at day 4 that survived to weaning at 21 days) 64.4 89.3
*Two females in the exposure group destroyed their litters at birth. One female died in parturition.
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- A screening for reproductive / developmental toxicity available (Key study - Klimich score 1) and two supporting developmental toxicity studies.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the available data, no classification for fusidic acid is proposed for reproduction (fertility and developmental toxicity).
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.